A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

PHASE2CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

November 15, 2017

Primary Completion Date

July 18, 2022

Study Completion Date

July 18, 2022

Conditions
Primary MyelofibrosisAnemia
Interventions
DRUG

Luspatercept

Luspatercept is a recombinant fusion protein consisting of a modified form of the extracellular domain of the human active in receptor type IIB linked to the IgG1 Fc domain. Luspatercept, through a mechanism of action different from erythropoietin, works to correct ineffective erythropoiesis by promoting late-stage maturation of erythroblasts.

Trial Locations (47)

10029

Local Institution - 104, New York

Mount Sinai Medical Center, New York

20089

Istituto Clinico Humanitas, Rozzano (MI)

Local Institution - 303, Rozzano (MI)

21100

Local Institution - 302, Varese

Ospedale di Circolo di Varese, Varese

24127

Azienda Ospedaliera Papa Giovanni XXIII, Bergamo

Local Institution - 304, Bergamo

27100

Fondazione IRCCS Policlinico San Matteo, Pavia

Local Institution - 301, Pavia

29609

CHRU de Brest - Hopital Morvan, Brest

Local Institution - 203, Brest

32224

Local Institution - 101, Jacksonville

Mayo Clinic - Jacksonville, Jacksonville

32763

Local Institution - 107, Orange City

Mid Florida Hematology and Oncology Centers, PA, Orange City

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Local Institution - 108, Tampa

44195

Cleveland Clinic, Cleveland

Local Institution - 109, Cleveland

50134

Azienda Ospedaliera Universitaria Careggi, Florence

Local Institution - 300, Florence

57105

Avera Research Institute, Sioux Falls

Local Institution - 105, Sioux Falls

62307

Centre Hospitalier de Lens, Lens

Local Institution - 201, Lens

75010

Hopital Saint Louis, Paris

Local Institution - 200, Paris

77030

Local Institution - 100, Houston

MD Anderson Cancer Center The University of Texas, Houston

78229

Local Institution - 106, San Antonio

University of Texas Health Science Center at San Antonio, San Antonio

85054

Local Institution - 102, Phoenix

Mayo Clinic - Arizona, Phoenix

94305

Local Institution - 103, Stanford

Stanford Cancer Center, Stanford

94805

Gustave Roussy, Villejuif

Local Institution - 202, Villejuif

BT9 7AB

Belfast Health and Social Care Trust, Belfast Northern Ireland

CF14 4XW

Local Institution - 404, Cardiff

University Hospital of Wales, Cardiff

OX3 7LE

Local Institution - 400, Headington, Oxford

University of Oxford, Headington, Oxford

SE1 9RT

Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital, London

Local Institution - 403, London

W12 0HS

Imperial College London, London

Local Institution - 402, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY

NCT03194542 - A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence | Biotech Hunter | Biotech Hunter